Shots:

• Pearl Bio and Merck have signed a license, collaboration and option agreement for the discovery of biological therapies consisting of non-standard amino acids for treating cancer
• The partnership will utilize Pearl’s GRO technology, capable of operating in both cell-based & cell-free systems, as well as proprietary tethered ribosomes to encode synthetic monomers for targeting epitopes that were previously not accessible
• As per the agreement, Pearl is entitled to receive a total of ~$1B comprising of upfront, option and milestones along with potential sales-based royalties for the approved drugs discovered under the partnership

Ref: Businesswire | Image: Pearl Bio

Related News:- Numab Therapeutics and Ono Pharmaceutical Join Forces for the Development of NM49 for Treating Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com